Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Rhea-AI Summary
Mineralys Therapeutics (Nasdaq: MLYS) appointed Jeffrey A. Munsie as Chief Legal Officer, effective March 24, 2026. Mr. Munsie has ~25 years of biopharma legal experience, including prior CLO roles at Orbital Therapeutics, Concert Pharmaceuticals, and Merrimack.
The Compensation Committee granted inducement awards on March 23, 2026: a 90,000-share stock option and 67,900 RSUs, vesting over four years with standard 25% first-year vesting, under the 2025 Employment Inducement Incentive Award Plan per Nasdaq Rule 5635(c)(4).
Positive
- None.
Negative
- None.
News Market Reaction – MLYS
In the Mar 24 session, MLYS declined 3.26%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.3% during that session. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 16 | Inducement equity awards | Neutral | -2.8% | Reported stock option and RSU inducement grants to a new non-executive hire. |
| Mar 12 | Earnings and update | Positive | -3.0% | Q4 2025 results with NDA acceptance, strong cash of $656.6M, and trial updates. |
| Mar 09 | NDA and trial data | Positive | +4.4% | FDA accepted lorundrostat NDA and Phase 2 Explore-OSA data showed BP benefit. |
| Mar 09 | Earnings date notice | Neutral | +2.4% | Announced schedule and access details for upcoming Q4 and full-year call. |
| Feb 26 | Inducement equity awards | Neutral | +0.8% | Announced inducement option and RSU awards for a new non-executive employee. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including positive regulatory and earnings updates, often saw modest or negative next-day moves, with only the NDA acceptance producing a stronger gain. Routine inducement awards have elicited small reactions.
Over the past month, Mineralys issued several updates, from NDA acceptance for lorundrostat with a PDUFA date of December 22, 2026 to Q4 2025 financials highlighting $656.6 million in cash and narrowed losses. The company has also repeatedly reported inducement equity awards under Nasdaq Listing Rule 5635(c)(4). Today’s legal leadership hire and associated inducement grants fit into this pattern of organizational and governance build-out alongside regulatory progress.
Key Terms
chronic kidney disease (CKD) medical
obstructive sleep apnea (OSA) medical
inducement stock option award financial
restricted stock unit financial
Nasdaq Listing Rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced the appointment of Jeffrey A. Munsie as Chief Legal Officer.
“Jeff brings deep life sciences experience across critical stages of growth, from preclinical through commercialization,” said Jon Congleton, Chief Executive Officer of Mineralys. “His strategic counsel, strong leadership, and proven track record will be instrumental in strengthening our legal and compliance capabilities.”
Mr. Munsie joins Mineralys with nearly 25 years of comprehensive legal experience in the biopharma industry. Most recently, he served as Chief Legal Officer and Secretary at Orbital Therapeutics, where he oversaw IP strategy, contracting, compliance, and transactions. Earlier in his career, he held legal leadership roles at Concert Pharmaceuticals and Merrimack Pharmaceuticals, and he started his career in the corporate department at Wilmer Cutler Pickering Hale and Dorr in Boston. Mr. Munsie earned a J.D. from Harvard Law School and an A.B. from Dartmouth College.
“I am thrilled to join Mineralys at such an important point in the company’s growth,” said Mr. Munsie. “I look forward to partnering with the team to advance lorundrostat and help bring it to as many appropriate patients as possible.”
Additionally, on March 23, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 90,000 shares and an inducement restricted stock unit award covering 67,900 shares of Mineralys common stock to Mr. Munsie.
The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option award will vest over a four-year period, with
About Mineralys
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
About Lorundrostat
Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as CKD and OSA. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated a 40
The Company has now completed six late-stage clinical trials of lorundrostat supporting the efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN and rHTN. This includes two pivotal, registrational trials, including the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial, which support the robust, durable and clinically meaningful reductions in systolic BP by lorundrostat. Lorundrostat was well tolerated in both trials with a favorable safety profile.
Forward-Looking Statements
Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the anticipated timing of the U.S. Food and Drug Administration’s (FDA) review of the Company’s accepted New Drug Application (NDA) and any subsequent regulatory approval of lorundrostat; and the planned future clinical development of lorundrostat and the timing thereof. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: topline results that we report are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial; any delays in the FDA’s review of our accepted NDA, including as a result of a government shutdown or reductions in agency funding or personnel, the results of our clinical trials, including the Advance-HTN and Launch-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for regulatory approval of lorundrostat; later developments with the FDA may be inconsistent with the feedback from prior meetings, including whether the proposed pivotal program will support registration of lorundrostat following the FDA’s review of our NDA submission; our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs and other trade policies, and the potential for a local and/or global economic recession; our ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Tanabe Pharma Corporation to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com
